TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents/guardian are willing and able to sign an informed consent form~* Age 5-18 years~* Diagnosis with type 1 diabetes for up to 2 months prior to screening~* Peak C peptide \> o.2 pmol/mL~Exclusion Criteria:~* The patient has any significant disease or conditions, including psychiatric disorders that in the opinion of the principal investigator might interfere with patient's compliance or ability to complete the study~* Any concomitant disease that might impact body composition, physical activity level and/or eating habits~* Active celiac disease, hashimoto thyroiditis or uncontrolled Graves' disease~* Down syndrome, Turner, inflammatory bowel disease~* Patients treated with antipsychotic drugs, steroids, or other drugs that might affect body weight and appetite.~* Patient who suffers from eating disorders~* Patients participating in other device or drug studies

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Mediterranean Diet (Type: EXPERIMENTAL): Mediterranean Diet
- Regular nutritional instructions (Type: ACTIVE_COMPARATOR): Regular nutritional instructions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed stage III-IV HNSCC, pathologically confirmed (HNSCC from unknown primary sites are allowed)~* No evidence of distant metastasis~* No prior radiation therapy to the head and neck sites.~* Able to sign a study-specific informed consent form.~* Women of childbearing potential and men with partners capable of producing offspring must be willing to practice acceptable methods of birth control to prevent pregnancy.~* Left ventricular ejection fraction (LVEF) within the institutional normal range as measured by ECHO (If ECHO cannot be performed or if the Investigator feels that it is not conclusive to evaluate LVEF, then a MUGA scan should be performed).~* Having one of the following parameters that would preclude the use of concurrent CRT:~  * ECOG PS \> 2.~ * Creatinine \> 1.3 or calculate or measure creatinine clearance \< 60 ml/min.~ * AST or ALT \> 1.5 times normal limit but \< 3 times normal limit~ * Total bilirubin \> 1.5 mg/dL but \< 3mg/dL~ * History of hearing loss that would preclude cisplatin chemotherapy. These would include the existing need of a hearing aid or a \>= 25 decibel shift over 2 contiguous frequencies on a pretreatment hearing test.~ * Pre-existing peripheral neuropathy that would preclude cisplatin chemotherapy~ * Refuse or cannot tolerate chemotherapy~* Age 18 years or older~Exclusion Criteria:~* Known hypersensitivity to lapatinib or any of the excipients of this product (quinazolines).~* Uncontrolled angina, arrhythmia or congestive heart failure at the time of HNSCC diagnosis and treatment.~* History of myocardial infarction \< 6 months from study entry.~* Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.~* Prior treatment with EGFR or Her2/Neu directed therapies.~* HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with Lapatinib.~* Absolute neutrophil count \< 1500/uL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy and Lapatinib with DCE-MRI (Type: EXPERIMENTAL): DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maintaining a Prone Position After Use of an Epidural Blood Patch for the Treatment of Post-dural Puncture Headache

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient was informed about the implementation of the study, its objectives, constraints and patient rights~* The patient has signed the informed consent~* The patient must be affiliated or beneficiary of a health insurance plan~* The patient is available for follow up concerning her hospital stay~* The patient has a post-dural puncture headache after a vaginal delivery. The diagnosis of post-puncture headache is retained on the basis of a frankly postural character for the headache, triggered or exacerbated by orthostatic position and relieved by recumbency.~* The patient has an indication for a blood patch~Exclusion Criteria:~* The patient is participating in another interventional study, with the exception of the following studies: Papillo PMA (2013-A00538-37); DG-Postpartum (2013-A00277-38); ElastoMAP (2013-A01148-37); ElastoDéclench (2014-A00828-39); LXRs(2009-A00968-49); OASIS II (2013-A00773-42); GrossPath (2014-A01120-47).~* The patient is in an exclusion period determined by a previous study~* The patient is under guardianship, curatorship or under judicial protection~* The patient refuses to sign the consent~* It is not possible correctly inform the patient~* The patient is pregnant~* The patient has a contra-indication (or an incompatible combination therapy) for a necessary treatment in this study~* The patient was delivered by cesarean section

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- The study population (Type: EXPERIMENTAL): The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.~Intervention: Prone position for 1 hour after blood patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Perineal Local Infiltration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal age \> 18 years of age~* Gestational age≥34 weeks of gestation~* Vaginal delivery~* Perineal laceration (2PT/Epi)~* Effective epidural anesthesia~* No known hypersensitivity to bupivacaine or amino-amide anesthetics~Exclusion Criteria:~* Medical history of a chronic pain syndrome~* Intrapartum morphine use

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Bupivacaine arm (Type: ACTIVE_COMPARATOR): The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
- Control arm (Type: SHAM_COMPARATOR): Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Real Time Measurement of Autonomous Nervous System for the Detection of Brain Death

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* severe cerebral lesions~* admitted in intensive care units~Exclusion Criteria:~* neoplastic pathology~* prior myocardiac infarction~* hearth failure~* atrial fibrillation~* insulin-treated diabetes mellitus~* cardiac pacemaker

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNA group (Type: None): This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
- Clinical group (Type: None): This group will have a conventional clinical analysis during its intensive care hospitalisation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All PD or TP patients 18-99 years old~Exclusion Criteria:~* Any other surgery than PD or TP~* High risk patients~* Refusal for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Enchanced recovery after surgery protocol (Type: EXPERIMENTAL): ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
- Standard protocol (Type: NO_INTERVENTION): Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Post Treatment Comparison Intramedullary Nail vs. Nonoperative Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A displaced transverse or oblique midshaft clavicle fracture with or without comminution~* Must be 12 ± 2 months to 36 ± 2 months post-treatment~* Must have received nonoperative treatment or operative treatment with a CRx™ device, no other devices, for their clavicle fracture~* Male or female at least 18 years of age~* Able to understand the requirements of the study, provide a written informed consent and comply with the study protocol~* Ability to understand and provide written authorization for use and disclosure of personal health information~Exclusion Criteria:~* Open, or segmental clavicle fracture~* Any clavicle or upper extremity fracture previous, concurrent, or subsequent to the study fracture~* Removal of the CRx™ device within 8 weeks of the study visit~* History of alcoholism~* Currently on chemotherapy or radiation therapy~* Habitual use of narcotic pain medications prior to injury or after injury for reasons other than clavicle pain~* Currently on worker's compensation~* History of a metabolic disorder affecting the skeletal system other than osteoarthritis or osteoporosis~* Rheumatoid arthritis or other inflammatory arthropathies.~* History of chronic pain issues for reasons other than clavicle pain or psychiatric disorder that precludes reliable follow-up.~* Women that are pregnant or think that they might be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group - Nonoperative (Type: None): Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
- Test Group - Intramedullary Nail (Type: None): Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electric Impedance Tomography

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing cardiac surgery which requires placement of pulmonary catheter~* Patients with right heart catheterization for diagnostic or therapeutic reasons~Exclusion Criteria:~* Patient unable to understand the study~* Patient unable to provide written consent or refusing his/her participation~* Patient suffering from a severe valvular insufficiency~* Patient allergic to ECG electrodes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Tomographie par impédance électrique (Type: EXPERIMENTAL): Tomographie par impédance électrique

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The investigators will enroll Veterans who fulfill the following criteria:~* stage 3, 4, or 5 CKD (estimated glomerular filtration rate of less than 60 ml/min/1.73 m2) on at least two separate occasions greater than 3 months apart; and~* candidates for EPO therapy as per the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines (hemoglobin \< 10 gm/dL and anemia of CKD).~Exclusion Criteria:~The investigators will exclude any Veteran who meets any of the following criteria:~1. pregnant, planning to become pregnant in the next year, or breast feeding;~2. uncontrolled hypertension (blood pressure \> 180/100 mm Hg despite optimal antihypertensive medications);~3. active gastrointestinal bleeding (visible blood or positive tests for stool occult blood accompanied by a decrease in hemoglobin);~4. likely to have EPO resistance;~5. an adverse cardiovascular event in the prior three months;~6. active or recent (within the last 3 months) severe, systemic infection;~7. active inflammatory disease such as lupus, rheumatoid arthritis, or vasculitis requiring immunosuppressive or immunomodulatory medications;~8. history of solid organ transplantation;~9. expected off-dialysis survival of less than one year (as determined by the estimated glomerular filtration slope and the treating physician;~10. active cancer (undergoing chemotherapy or radiation within the last 3 months) or primary bone marrow disease such as myelofibrosis; or~11. a contraindication for an MRI or individuals who cannot comply with the study protocol. The investigators will exclude healthy subjects that meet a, b, f, g, h, or j.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose erythropoietin (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
- High dose erythropoietin (Type: EXPERIMENTAL): Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Apnea in Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Homozygous HbS (Hemoglobin S) (SS) patients,~* aged between 15 and 3 months and 50 years old,~* in steady state (i.e. without vaso-occlusive crisis or recent blood transfusion),~* followed by the sickle cell center of the Hospices Civils de Lyon,~* and showing symptoms of OSA.~Exclusion Criteria:~* Patients receiving treatment of OSA,~* recent blood transfusion (less than 2 months),~* patients not at steady state (VOC or acute chest syndrome less than 2 months),~* pregnancy.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- SS patients (Type: ACTIVE_COMPARATOR): Homozygous sickle cell patients~Each patient will undergo the following:~1. polysomnography and oxygen saturation exam~2. calculation of VOC rate within the two previous years~3. Blood samples~4. Physiological measurements
- SS patients apneic (Type: EXPERIMENTAL): Homozygous sickle cell patients after one year of continuous positive airway pressure treatment~Each patient will undergo the following:~1. polysomnography and oxygen saturation exam~2. calculation of VOC rate within the two previous years~3. Blood samples~4. Physiological measurements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous Positive Airway Pressure (CPAP) in Heart Remodeling by Magnetic Resonance Imaging (MRI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients free of comorbidities with severe Obstructive Sleep Apnea by polysomnography.~* Healthy volunteers (no obstructive sleep apnea and no comorbidities) matched for age, sex and body mass index.~Exclusion Criteria:~* Subjects older than 60 years~* Body mass index (BMI) \>40 kg/m2~* Diabetes mellitus~* Hypertension~* Cerebrovascular disease~* Valvular heart disease~* Renal failure~* Current or past smoking history~* Chronic use of any medication

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 Control (Type: PLACEBO_COMPARATOR): No treatment
- 2 CPAP (Type: EXPERIMENTAL): Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Greater than 18 years of age~* Treated for at least the last 3 months with a daily dose of atorvastatin 40 mg~* Existing coronary heart disease and cholesterol \> 4.0 mmol/l~Exclusion Criteria:~* Uncontrolled diabetes~* Elevated liver function tests~* Elevated creatine kinase (ck)~* Triglycerides (tg) \> 4.5 mmol/l~* Drug or alcohol dependency within 6 months prior to visit 1~* Woman receiving hormonal therapy who have not been maintained on a stable dose and regimen for at least 8 weeks and are willing to continue the same regimen for the duration of the study~* Woman of childbearing potential not using an acceptable method of birth control~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic HBV；~* Receiving anti-HB viral therapy；~* 10 IU/ml≤HBsAg≤3000 IU/ml.~Exclusion Criteria:~* Patients co-infected with hepatitis C virus, HIV, HAV, HDV, HEV;~* Liver cirrhosis;~* Hepatocellular carcinoma;~* Autoimmune liver disease;~* Clinical hepatic decompensation;~* Fibroscan\>12 kPa;~* a. hemoglobin\<110g/L（female）\<120 g/L（male），platelet\<ULN，white blood cell\<2.5×109/L；b. bilirubin\>1.5 ×ULN，ALT\>2 × ULN，serum albumin\<35 g/L；c. INR\>1.5；d. serum creatinine \>1.5×ULN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- lowest dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single lowest dose of STSG-0002 Injection following protocol requirements
- low dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single low dose of STSG-0002 Injection following protocol requirements
- Intermediate dose treatment group (Type: EXPERIMENTAL): Subjects will receive one single intermediate dose of STSG-0002 Injection following protocol requirements
- A single high dose of treatment group (Type: EXPERIMENTAL): Subjects will receive one single high dose of STSG-0002 Injection following protocol requirements

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy